Clinical Trials
PIANO: A national pregnancy registry of women with IBD
This national prospective registry study is conducted to determine whether the rates of birth defects, miscarriages, premature births and other outcomes in women with inflammatory bowel disease (IBD) taking azathioprine/6MP or biologic therapy (Remicade, Humira, Cimzia, Tysabri, Stelara, Simponi, Entyvio, or Xeljanz) are different from those among IBD-affected women not taking these medications.
For more information, please visit the PIANO website.
PIANO Registry (pdf)
Kattah Lab
The Kattah Lab aims to understand the causes of Inflammatory Bowel Disease. We are particularly interested in how intestinal epithelial cells contribute to disease. The ultimate goal is to develop patient-tailored treatment strategies that maximize efficacy and minimize toxicity for individual patients.
For more information, please visit the Kattah Lab website.
AMETRINE: RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis
The AMETRINE study is a Phase III clinical trial by Genentech evaluating RO7790121, a potential treatment for moderately to severely active ulcerative colitis (UC). This drug targets TL1A, a protein involved in gut inflammation, to help reduce symptoms and maintain remission. The study is enrolling adults (16-80) who haven’t responded well to other UC treatments. By participating, individuals contribute to research that may improve future UC therapies.
For more information, please view the ICF below:
PALEKONA: GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis
The PALEKONA study is a Phase 2 clinical trial by Gilead evaluating tilpisertib fosmecarbil (GS-5290), an investigational drug designed to block Syk, a protein involved in inflammation, in adults with moderately to severely active ulcerative colitis. Participants will take either the study drug or a placebo for 12 weeks, with the option to continue treatment for up to 64 weeks.
For more information, please view the ICF below:
NORTHSEA: NST-6179 in adults with Intestinal Failure-Associated Liver Disease (IFALD)
NorthSea Therapeutics is conducting a Phase 2a clinical trial to evaluate the safety and effectiveness of Orziloben (NST-6179) in adults with Intestinal Failure-Associated Liver Disease (IFALD). This condition often affects individuals who have been on prolonged intravenous nutrition. Participants will receive either Orziloben or a placebo to assess the drug's impact on liver health.
For more information, please view the ICF below: